SEATTLE — In this Healio Video Perspective from OIS Retina, Richard Small previews a presentation that will cover phase 3 data on encapsulated cell therapy for the treatment of macular telangiectasia.
Two studies demonstrated statistical and clinical efficacy for the treatment of MacTel over 2 years, “but we also have data which actually shows that our technology and platform last much longer than 2 years,” he said.
Neurotech is preparing a license application for the FDA with the goal of having the platform on the market in 2024, according to Small.